Analyte Testing in Risk Assessment and Management of Cardiovascular Disease
Blue Cross Blue Shield of Arizona's medical policy 'Analyte Testing in Risk Assessment and Management of Cardiovascular Disease' (original, current and last-criteria-revision effective date 10/27/26) sets coverage criteria: a single lipoprotein(a) test for atherosclerotic CVD risk assessment and apolipoprotein B in patients on lipid-lowering therapy (with one listed qualifying diagnosis) are medically necessary, while hs-CRP testing (with three documentation elements), other non-traditional lipid/non-lipid analytes, lipoprotein-associated phospholipase A2, and CVD risk panels are described as experimental or investigational when specified criteria are met. Billing staff should align orders, documentation and claim coding for these analytes with the stated criteria.